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Abstract
Celiac disease is a common autoimmune disorder characterized by an intestinal inflammation triggered by gluten, a storage
protein found in wheat, rye and barley. Similar to other autoimmune diseases such as type 1 diabetes, psoriasis and
rheumatoid arthritis, celiac disease is the result of an immune response to self-antigens leading to tissue destruction and
production of autoantibodies. Common diseases like celiac disease have a complex pattern of inheritance with inputs from
both environmental as well as additive and non-additive genetic factors. In the past few years, Genome Wide Association
Studies (GWAS) have been successful in finding genetic risk variants behind many common diseases and traits. To
complement and add to the previous findings, we performed a GWAS including 206 trios from 97 nuclear Swedish and
Norwegian families affected with celiac disease. By stratifying for HLA-DQ, we identified a new genome-wide significant risk
locus covering the DUSP10 gene. To further investigate the associations from the GWAS we performed pathway analyses
and two-locus interaction analyses. These analyses showed an over-representation of genes involved in type 2 diabetes and
identified a set of candidate mechanisms and genes of which some were selected for mRNA expression analysis using small
intestinal biopsies from 98 patients. Several genes were expressed differently in the small intestinal mucosa from patients
with celiac autoimmunity compared to intestinal mucosa from control patients. From top-scoring regions we identified
susceptibility genes in several categories: 1) polarity and epithelial cell functionality; 2) intestinal smooth muscle; 3) growth
and energy homeostasis, including proline and glutamine metabolism; and finally 4) innate and adaptive immune system.
These genes and pathways, including specific functions of DUSP10, together reveal a new potential biological mechanism
that could influence the genesis of celiac disease, and possibly also other chronic disorders with an inflammatory
component.
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Introduction
Celiac disease (CD) is a common chronic disease and even
though most often diagnosed in early childhood, it can present
itself at any age. Most of the individuals with CD remain
undiagnosed and an estimated 2% of the Swedish population is
affected without having been diagnosed [1]. Ongoing disease will
increase the overall risk for developing other chronic inflammatory
diseases, neurological manifestations and malnutrition disorders.
CD is the only autoimmune disorder where the actual genes
responsible for the association in HLA are known (HLA-DQA1 and
HLA-DQB1) [2]. In the past few years Genome Wide Association
Studies (GWAS) have had tremendous success in identifying new
genes, or gene regions, that influence common diseases. These
studies use several hundreds of thousands of genetic markers
(single nucleotide polymorphisms, SNPs) across all human
chromosomes in order to pin down the chromosomal locations
of genes, which could influence the disease.
A large joint effort has been done, not the least in CD, and 40
new CD-associated genetic regions marked by SNPs have been
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discovered [3–7]. However, these genes cannot account for all CD
heritability, and part of the genetic variance that influences disease
development is still unknown [8].
Most GWAS so far have been performed on case control
samples. A case control study design has some advantages
compared to using a family study design. For example, in a case
control design it is possible to select a perfectly matched set of
controls to increase the chance of discovering susceptibility genes,
and furthermore, cases and controls are usually easier to collect
than individuals from the same family. However, using a family
material can be a very good complement to a case control design.
First of all, families with several affected members are likely to
have a stronger genetic component compared to sporadic cases.
Familial cases tend to be enriched for disease-predisposing alleles
and there is an increased power especially for detecting rare
genetic variants [9]. Another important fact is that statistical
analyses based on family data are robust against population
stratification. Already in their paper from 1996, Risch and
Merikangas suggested that all sib-pair families collected for non-
parametric linkage analysis in complex diseases, should be re-run
‘‘Genome-Wide’’ using SNP markers and the potentially more
powerful Transmission Disequilibrium Test (TDT) [10]. The
TDT test in sib-pairs is a test of linkage in the presence of
association. Hereafter we refer to whole genome sibling TDT as
‘‘Linkage GWAS’’.
In this study, we aimed to uncover additional genetic factors in
CD by performing a Linkage GWAS using 206 affected children
(sib-pairs) within 97 nuclear families using the TDT test. In
addition to the Linkage GWAS we explored gene-gene interac-
tions and pathway analyses. We also performed a non-parametric
linkage (NPL) analysis and compared the results with the published
linkage analysis, with microsatellite markers, performed in the
same set of families previously [11]. Furthermore, quantitative
PCR was used to investigate levels of gene expression in small
intestinal biopsies from additional patients with CD autoimmunity
(CAI) and control patients. Finally, we stratified the TDT analysis
on HLA genotype. It has been shown that carrying DQB1*02 on
both chromosomes (i.e. being homozygous), confers higher risk of
developing CD as compared to heterozygote individuals [12]. It is
therefore conceivable that heterozygote individuals may require
more additional risk factors outside HLA, in order to accumulate
sufficient risk to develop CD, compared with homozygous
individuals. Based on this assumption we stratified the patient in
an HLA low-risk group and an HLA high-risk group. By
stratifying the Linkage GWAS, we expected to uncover even
more of the so-called ‘‘missing heritability’’ in CD. This strategy
could identify different risk factors all together or perhaps a more
likely scenario is that the same risk factors outside HLA would just
be more common in the HLA low-risk group.
Results
Genotyping and Imputation
We included single nucleotide polymorphism (SNP) markers
that had a call rate above 97%, which led to the exclusion of 1.3%
of the Omni Express and 0.6% of the 660W-Quad SNP markers.
Out of the 127,535,126 imputed genotypes, 88.3% had a posterior
probability of over 0.95. Approximately 90% of the 944,512 SNP
markers had a minor allele frequency of at least 0.01 after
imputation.
Transmission Disequilibrium Test (TDT)
All markers from the TDT analysis are shown in Figure 1a. As
expected, the region around the CD associated HLA genes on
chromosome 6 showed the strongest association with the most
significant p-value reaching 4.9610221 at marker rs424232. In
Table 1, we present the 35 most significant associations found
outside of HLA (HLA defined as SNP markers located within 27–
34 Mb on chromosome 6). The most significant finding outside of
the HLA region was the marker rs12734338 on chromosome 1,
including the PPP1R12B gene.
HLA Stratified Transmission Disequilibrium Test (TDT)
In Figure 1b and Table 2, we present results from the TDT
analysis stratified on the HLA-DQ risk factor. For this analysis 115
affected offspring trios were included in the ‘‘low-risk’’ group and
88 trios were put in the ‘‘high-risk’’ group. A region including the
DUSP10 gene (also known as MKP5) reached genome-wide
significance (p-value = 3.861028) in the low-risk group. Figure 1c
presents this region including the most associated SNPs plotted on
the x-axis using SNAP.
Interaction Analyses
Since some markers just below genome-wide significance are
still expected to be true findings, we wanted to try and separate
these from the, in fact, true negative findings (those that show
linkage and association close to genome-wide significance just by
chance). In total, 603 SNP markers from 383 independent regions
and their surrounding genes were identified by three inclusion
criteria (Fig. 2 and Table S1). These genes were subsequently used
for pathway and two-locus interaction analyses.
Two-locus interaction analysis. Two-locus interaction
analysis, identified 582 SNP pairs with a p-value of less than
1.061024 for the test comparing the model M0 of no association
and the general two-locus model MG. Out of these, 101 pairs from
87 regions deviated significantly (p,0.05) from a purely multipli-
cative model (MM), which is the best fitting model when at least
one of the SNP markers is false. Under the null hypothesis we
expect to find 29 such pairs. The 101 pairs showed either epistasis
(individuals carry both risk alleles) or evidence of heterogeneity
(individuals carry either the one or the other risk allele from the
two loci).
The results with a p-value ,1.061024 for epistasis and those
with high p-value (.0.05), which represent pairs that did not show
convincing deviation from the heterogeneity model are listed in
Table 3 and 4. Several loci were in an epistatic relationship with
HLA; rs4899272 (ACTN1), rs1073933 (COX7C), rs10482751
(TGFB2), rs571879 (APPL1) and rs7590305 (FABP1). Also,
previously identified susceptibility loci for CD were involved in
Figure 1. Manhattanplot of the TDT p-values. a) The location of all genotyped SNPs on chromosomes 1–22 and X plotted on the x-axis. –
log10(p-value) result for each SNP and all transmissions on the y-axis. b) The location of all genotyped SNPs on chromosomes 1–22 and X plotted on
the x-axis. –log10(p-value) result for each SNP and all transmissions, to children in the low risk group, on the y-axis. c) Regional plot of association
results and recombination rates, within the region surrounding DUSP10, generated by SNAP (http://www.broadinstitute.org/mpg/snap/ldplot.php).
The x-axis show 500 kb around the most associated SNP. Genomic locations of genes within the region of interest (NCBI Build 36 human assembly)
were annotated from the UCSC Genome Browser (arrows). The left y-axis show –log10(p-value) and estimated recombination rates (cM/Mb) from
HapMap Project (NCBI Build 36) are shown in light blue lines.
doi:10.1371/journal.pone.0070174.g001
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several interactions: rs4899272 (ACTN1), rs6741418 (STAT1, GLS),
rs13096142 (CCR1,2,3,5), rs10197319 (ICOS, CTLA4) and
rs870875 (CD247).
Pathway analysis. Biological functions clustered by Ingenu-
ity Pathway Analysis (IPA) and Genetrail [13] are shown in
Table 5, 6 and 7. Several clusters were significant after correction
for multiple comparisons. The most significant network implicated
by IPA included DUSP10 (Fig. 3 and Table 8). The second top
network included the MHC complex (HLA) and the third top
network included LPP, which is located within the most
significantly non-HLA associated region identified in CD so far
[3].
Gene Expression
Out of the 34 selected target genes, three were from the top
associated SNPs (DUSP10, SVIL and PPP1R12B) and the
remaining were genes identified from the two-locus and pathway
analysis. Eight genes showed significant up- or down-regulation
after correction for multiple testing using Bonferroni correction
(Fig. 4). For the top associated genes, several transcript variants
were tested (Table 9). For the PPP1R12B gene, Isoform c and d
(transcript variants NM032103.2 and NM032104.2) also known as
the small subunit (sm-M20) of myosin light chain phosphatase,
show significant up-regulation in patients with CD autoimmunity
compared to control patients. An additional ten genes showed
nominally significant differences in expression (Table 9).
Non-parametric Linkage (NPL)
The strongest linkage outside of HLA was detected in
chromosome regions 5q23.2-q33.1, and 1q32.1. In total, thirteen
regions with an NPL point wise p-value below 0.01 were detected
(Fig. 5 and Table 10). In our previous linkage-scan, using almost
the same set of families, we detected only one region (11q23-25)
with a point wise p-value below 0.01 [14]. The reason for the
improved results is mainly the almost perfect information content
achieved by a dense set of highly successful SNP markers
compared to a relatively sparse set of less successful microsatellite
markers. Also in the NPL analysis, the PPP1R12B gene was
located in one of the top regions (1q32.1).
Discussion
This study confirmed some previous GWAS findings and in
addition, it established a new genome-wide significant region
containing the DUSP10 gene. The top markers, rs12144971 and
rs4240931 showed a substantial effect size in the HLA low-risk
group with a transmitted versus non-transmitted allele ratio of 3.11
(Table 2).
DUSP10, TNF-a and Tissue Transglutaminase (TGM2)
The protein product of DUSP10 preferentially binds to the
stress-activated p38 MAPK (mitogen-activated protein kinase) and
plays an important role in regulating chemokine induction after
infection by various pathogens [15], and in coordinating MAPK
activity in response to oxidative stress [16]. In previous studies,
both p38 MAPK and DUSP10 have been shown to activate TNF-
a [17,18], of which one also demonstrates that TNF-a up-
regulates TGM2 (the gene encoding the main autoantigen in CD
[19]) in intestinal mucosa from untreated CD patients [17].
Whether this up-regulation of TGM2 is of importance for the
immune response leading to formation of IgA-tTG and IgG-tTG
autoantibodies, the serological markers for CD is still unresolved.
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Pathway Analyses
In order to discover possible functional connections between
DUSP10 and other genes, we analyzed genes surrounding the top
603 markers. A total of 845 genes were used in the analysis.
Ingenuity pathway analysis (IPA) included DUSP10 within the
most significant network. Also part of this network were GLS and
RGS1, two genes previously identified within significant GWAS
loci [3], as well as the insulin (INS) gene, and the immune
regulatory nuclear factor kappa B (NF-Kb) complex (Fig. 3 and
Table 8). The second top network included the MHC complex
(HLA) and also several genes within already identified GWAS loci:
ACTN1, CD247, CCR5, ICOS and STAT1 [3]. In addition, both
IPA and GeneTrail [13] identified T2D genes as the most
significantly overrepresented gene cluster after correction for
multiple testing (Table 5 and 6). Among this set of genes
surrounding the 603 markers, many genes belonged to growth
and nutrient signaling pathways, for example, INS, INSR, EGF,
POMC, TIPRL and PRR5L. There were also related genes directly
involved in energy metabolism; PDK1, COX7C, COQ3 and GLS.
Overlapping Results with Other GWAS Findings
Surprisingly, four out of six top loci identified by a GWAS for
anorexia nervosa [20] and two out of three loci involved in plasma
glucose levels in type 1 diabetic patients [21] were among our 603
and 35 best SNP markers respectively. One of the genes in
anorexia, namely AKAP6, is also associated to fasting insulin-related
traits as well as the autoimmune disease Ankylosing spondylitis
[22]. Of the 40 identified regions in CD, seven regions overlap
with our 603 SNP list (LPP, STAT4/GLS, RGS1, CCR1/CCR3,
PUS10, ICOS/CTLA4 and CD247). Out of the 69 regions reported
in the GWAS catalog for type 1 diabetes, eight overlap with the
regions reported in this study and out of those eight, CTLA4/ICOS
also overlap with the previously reported CD associations.
We compared minor allele frequencies between the previous
CD GWAS by Dubois et al. and our GWAS. In their top 42
associations, there was no SNP below a minor allele frequency of
0.08. In our top 42 associations, we identified five SNPs with a
minor allele frequency below 0.06. This observation could just be
a chance finding or perhaps an indication that rare variants are
easier to discover using families. We also identified a relatively rare
variant in the LPP gene region (rs17283813), with a minor allele
frequency of 0.075. This SNP was not at all significant in the
GWAS by Dubois et al. (Table S1).
Neither was there an association with the DUSP10 region in the
GWAS by Dubois and co-workers. The associated markers in the
DUSP10 region in our GWAS have a minor allele frequency
around 0.5 and are hence very common in the population. It is
difficult to say if this is a population specific effect or if DUSP10
could be detected in an HLA stratified population from another
ethnicity. Interestingly, the DUSP10 region has also been identified
as a risk factor for colon cancer by a meta-analysis of three GWAS
from the UK. This is an indication that colon cancer and CD
could share genetic risk factors.
Key Metabolic Regulators as well as the Top Associated
gene PPP1R12B were Differently Expressed in CD Cases
Compared to Controls
Another important finding was the difference between cases and
controls and their gene expression patterns in the small intestine.
Eight of the 34 candidate genes selected for quantitative
measurements of gene expression, including PPP1R12B, PDK1,
GLS, PRR5L and the INSR, showed significant up or down
regulation of mRNA levels in cases compared to controls (Fig. 4).
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Figure 2. Illustration of the three inclusion criteria used for pathway and interaction analyses. The first criteria of p-values less than
3.061024 in the linkage TDT analysis resulted in a total of 477 markers. The second criteria included a comparison of the results from this study with
the results from the study by Dubois et al. [3]. We included 118 SNPs that had a simple score based on a combined p-value less than 5.061025 and in
the same allelic direction in both datasets. The third criteria involved selecting markers with a large effect size. We included 65 markers which had a
ratio of transmitted versus not transmitted (T/NT) alleles of over 5 or below 0.2, combined with a p-value of less than 2.061023.
doi:10.1371/journal.pone.0070174.g002
Table 3. The top epistasis interaction results from the 101 two-locus interaction analysis.
Snp 1 Genes chr Snp 2 Genes chr N P02 P12 PM2
rs2187668 HLADQ 6 rs4899272 ACTN1 14 95 4.0E-17 1.42E-13 4.E-02
rs204034 SHISA9 16 94 1.3E-14 1.09E-12 5.E-02
rs571879 APPL1 HESX1 IL17RD. DNHD2. ASB14 3 94 2.3E-15 5.21E-11 3.E-02
rs204999 HLA 6 rs1073933 COX7C 5 94 9.9E-14 9.27E-12 3.E-02
rs11836636 ATXN7L3B KCNC2 12 91 1.1E-12 8.15E-11 4.E-02
rs7745052 FBXL4. C6orf168. USP45. COQ3. POU3F2. SFRS18 6 92 2.3E-05 1.79E-05 4.E-02
rs10749738 FOXD3 1 rs1373649 BMPR1B 4 93 2.7E-05 1.78E-05 4.E-02
rs3860295 RASSF5 IKBKE 1 rs13096142 CCR5 CCR3 LTF CCR2 CCR1 3 95 1.1E-05 6.48E-06 1.E-02
rs9396802 KIF13A NUP153 FAM8A1 6 rs2194633 NETO1 18 95 3.8E-06 6.82E-06 2.E-02
rs9296204 MTCH1 PI16 6 rs4385459 LY96 JPH1 GDAP1 TMEM70 TCEB1 8 95 2.8E-05 9.91E-06 3.E-02
rs9397928 ARID1B* 6 rs2415836 FSCB* 14 93 2.8E-05 1.75E-05 3.E-03
rs1145212 APOA5 ZNF259 BUD13 11 rs10083673 MYO5A 15 95 6.6E-05 1.77E-05 2.E-03
rs7756191 DNAH8 6 rs1108001 NAV2 HTATIP2 DBX1 PRMT3 11 95 3.5E-05 2.60E-05 3.E-03
rs10197319 ICOS CTLA4 2 rs882820 SRL TFAP4 16 94 1.4E-05 3.03E-05 3.E-05
rs4899272 ACTN1 14 rs17703807 C15orf41 15 83 2.9E-05 8.68E-05 1.E-02
All SNP pairs which reached an interaction p-value of P12,1.0610
24, in addition to PM2,0.05.
*closest known gene. located .500 kb from associated SNP.
P02– p-value for the test statistic comparing the models M0 (no association) and the general model MG.
P12– p-value for the test test comparing the models MR (heterogeneity) and the general model MG.
PM2– p-value for the test comparing the models MM (multiplicative) and the general model MG.
doi:10.1371/journal.pone.0070174.t003
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This could very well be a consequence of an ongoing inflammation
or possibly also indicate an underlying metabolic difference.
Glutamine is converted to glutamate by the enzyme glutaminase
(GLS). In turn, glutamate can be converted to proline and
subsequently catabolized by the enzyme proline dehydrogenase
(PRODH) resulting in the production of reactive oxygen species
and apoptosis [23]. In the present study, we show that the
expression of GLS is down-regulated and PDK1 is up-regulated in
cases. Interestingly, a previous study has shown that cell lines with
a known familiar mutation for amyotrophic lateral sclerosis (ALS)
have the same expression pattern, with up-regulated PDK1 and
down-regulated GLS, as compared to the wild-type cell line [24].
PRR5L (also called Protor-2) belong to the TOR signaling
pathway. Our results show an up-regulated PRR5L expression in
cases (Fig. 4). Like DUSP10, the protein product from PRR5L has
been shown to stimulate an increased TNF-a expression [25].
Another gene, connected to the MAPK pathway and which was
identified both by our two-locus interaction analysis and in
significant biological functions implied by IPA, was the APPL1
gene. APPL1 is a binding partner of the protein kinase Akt2 and a
key regulator of insulin signaling [26]. It takes part in adiponectin
signaling to stimulate activity of p38 MAPK in muscle cells [27]
and is a critical regulator of the crosstalk between adiponectin
signaling and insulin signaling pathways [28]. We could detect
expression of both APPL1 and APPL2 in small intestinal biopsies
and a significantly lower expression of APPL2 was detected in the
CD autoimmunity cases as compared to controls (Fig. 4). Lower
expression of APPL2 levels lead to enhanced adiponectin
stimulated glucose uptake and fatty acid oxidation [29]. A SNP
(rs10861406) included in the top 603 list was located upstream of
the APPL2 gene, however the promotor of this gene was on the
opposite side of a recombination hotspot and therefore not
included in the gene list for pathway analyses.
The most significant finding from our non-stratified linkage
GWAS analysis was the association with the PPP1R12B gene
region. PPP1R12B is involved in smooth muscle contractibility and
mediates binding to myosin [30]. Myosin light chain phosphatase
from smooth muscle consists of a catalytic subunit (PP1c) and two
non-catalytic subunits, M130 and M20. The two non-catalytic
subunits are both encoded by the PPP1R12B gene. The M130
transcript was not differentially expressed between CD autoim-
munity and control patients while the small subunit ‘‘M20’’
showed a significantly higher expression in patients with CD
autoimmunity. (PPP1R12B_22 in Fig. 4) Several other genes
located close to top markers such as the PPP3CA, ACTN1, MYO1B,
MYO5A, MAPK1, PRKCH, PRKCQ, PRKACB, PRR5L and NTS
genes, are connected to smooth muscle when examining their
function by using KEGG [31] and Gene Ontology [32].
Table 4. The top heterogeneity results from the 101 two-locus interaction analysis.
SNP1 Genes chr SNP2 Genes chr N P02 P12 PM2
rs4899272 ACTN1 14 rs4820682 SRRD HPS4 TFIP11 ASPHD2 MIR548J
TPST2 CRYBB1 CRYBA4
22 95 7.1E-06 6.97E-02 2.E-02
rs4426448 DOK6 18 94 9.5E-06 6.80E-01 1.E-02
rs870875 CD247 1 94 9.4E-05 7.19E-02 3.E-02
rs4842007 PAEP 9 95 8.6E-06 5.66E-01 4.E-02
rs571879 APPL1 HESX1 IL17RD
DNHD2 ASB14
3 rs4385459 LY96 JPH1 GDAP1 TMEM70 TCEB1 8 94 4.1E-05 5.81E-01 5.E-02
rs7590305 FABP1 THNSL2 2 rs390495 MICAL3 22 93 7.0E-05 9.09E-01 3.E-03
rs7745052 FBXL4 C6orf168 USP45
COQ3 POU3F2 SFRS18
6 rs4930144 IGF2AS TH MRPL23 TNNT3 SYT8 ASCL2
TNNI2 LSP1 IGF2 INS-IGF2 INS H19
11 50 1.9E-05 5.30E-01 3.E-02
rs10749738 FOXD3 1 rs10498982 EPHA7* 6 93 2.0E-05 1.95E-01 4.E-02
rs2605393 STAC 3 63 7.3E-05 4.37E-01 4.E-02
rs2187668 HLADQ 6 rs11013804 KIAA1217 10 94 3.5E-14 8.40E-02 2.E-02
rs1676235 ESRRB ANGEL1 VASH1 14 43 2.0E-07 8.55E-02 3.E-02
rs958802 KANK4 L1TD1 INADL 1 rs2194633 NETO1 18 95 1.9E-05 5.55E-01 3.E-02
rs2345981 KHDRBS2 6 rs6495130 RYR3 15 94 6.1E-05 1.58E-01 3.E-02
rs11940562 PCDH7* 4 rs4905043 ITPK1 CHGA 14 44 4.6E-05 2.77E-01 2.E-02
rs4656538 POU2F1 1 rs2187668 HLADQ 6 94 3.0E-13 1.19E-01 5.E-02
rs3860295 RASSF5 IKBKE 1 rs7046385 SMC2 9 94 5.3E-05 1.07E-01 2.E-02
rs6741418 STAT1 GLS STAT4 2 rs10798004 C1orf25 C1orf26 IVNS1ABP RNF2 1 87 7.2E-05 7.68E-02 4.E-02
rs1571812 VLDLR 9 86 3.0E-05 9.19E-02 4.E-02
rs882820 SRL TFAP4 16 87 4.2E-05 3.52E-01 6.E-03
rs1470379 VIM 10 82 1.0E-05 3.70E-01 8.E-03
rs10946659 DCDC2 NRSN1 6 87 1.9E-06 6.64E-01 9.E-03
rs10482751 TGFB2 1 rs1571812 VLDLR 9 92 5.2E-05 1.86E-01 1.E-02
All SNP pairs which reached an interaction p-value of P12.0.05, in addition to PM2,0.05.
*closest known gene located .500 kb from associated SNP.
P02– p-value for the test statistic comparing the models M0 (no association) and the general model MG.
P12– p-value for the test test comparing the models MR (heterogeneity) and the general model MG.
PM2– p-value for the test comparing the models MM (multiplicative) and the general model MG.
doi:10.1371/journal.pone.0070174.t004
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The second most significant region in the HLA-stratified
analysis after DUSP10 contains the SVIL gene. The product of
this gene has been suggested to bind LPP [33]. In our two-locus
interaction analysis, the LPP locus and a locus containing KIF13A
was one of the 101 interaction pairs. KIF13A is a motor protein,
which shuttles vesicles containing AP-1 and the mannnose-6-
phosphate receptor [34]. KIF13A was significantly down-regulated
in intestinal biopsies from CD patients in our gene expression
analysis (Fig. 4). SVIL is associated with cell-focal adhesions
(substrate contacts), which are important for rapidly moving cells
such as for example immune cells but also for motility and polarity
of intestinal epithelial cells. SVIL mRNA was down-regulated in
our gene expression analysis, however, not significant after
correction for multiple testing.
Proline and Glutamine Metabolism - Part of a ‘‘Danger
Signal’’
Amoebiasis was one of the nominally significant pathways in the
GeneTrail analysis of genes surrounding the two-locus interaction
SNPs (Table 7). Several of these genes were also present together
with DUSP10 and the MHC class II genes in the two most
significant IPA generated networks (marked in bold text in
Figure 3. Ingenuity network 1. The top network identified by the Ingenuity IPA software using genes surrounding all 603 most associated SNPs
from the TDT analysis. Molecules in gray were present among the genes from our TDT analysis and molecules in white were added by the IPA
software. The DUSP10 gene is marked in yellow.
doi:10.1371/journal.pone.0070174.g003
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Table 5. Biological functions of genes surrounding the 603 top associated SNPs. Results from IPA.
Function
Annotation
p-value
(Raw)
B-H p-
value* Molecules Molecules
non-insulin-
dependent
diabetes
mellitus
0.0000057 0.025 ABCC8. ADRA1B. ADRA1D. AGT. APOA5. ATP10A. BCL2L11. CCR5. CD38. CNTNAP2. FOXP1. FTO. HFE.
HFE2. INS. INSR. KCNJ11. KIRREL3. KLF10. mir-154. mir-448. MTTP. PBX3. PIEZO2. PPARA. PPP3CA. PRDM10.
RGS5. VEGFA. ZMYM2
30
quantity of
metal
0.0000082 0.025 ABCC8. ADRA1B. AGT. APLP2. ATP2B3. BCL2. BMP2. BTK. CAMLG. CCR5. CD247. CD38. CHGA. CX3CR1.
CXCL13. DARC. DCN. DVL1. EGF (includes EG:13645). FBXL5. FCER1A. GNA14. GNB1. HFE. HFE2. IGF2. INS.
INSR. KCNJ11. LTF. NTS. NUCB2. POMC. PRL. PRNP. PTGDR2. RGS1. RYR3. SELL. SOD1. TRPM8. TXNIP.
VAV3. VEGFA
44
incorporation
of thymidine
0.000010 0.025 AGT. AKAP13. BMP2. CD40. EGF (includes EG:13645). IGF2. INS. INSR. PRL. THBS2. TNFSF13B. VEGFA. WT1 13
quantity of
Ca2+
0.000018 0.033 ABCC8. ADRA1B. AGT. ATP2B3. BCL2. BTK. CAMLG. CCR5. CD247. CD38. CHGA. CX3CR1. CXCL13. DARC.
DCN. DVL1. EGF (includes EG:13645). FCER1A. GNA14. GNB1. IGF2. INS. INSR. KCNJ11. NTS. NUCB2. POMC.
PRL. PRNP. PTGDR2. RGS1. RYR3. SELL. SOD1. TRPM8. VAV3. VEGFA
37
eye
development
0.000022 0.033 BID. BMPR1B. CD247. CHD7. CRYBB2. CX3CR1. DLX1. DNMT3A. EBF3. EGF (includes EG:13645). FJX1. FTO.
GJA3. H19. HESX1. IFT88. IGF2. IRX3. ITGA6. LUM. MITF. OGN. PAX5. PROM1. PRRX2. PYGO1. SEMA5A. SOD1.
STAT1. TGFB2. TH. THBS2. THRB. TUB. USH2A. VEGFA. WT1
37
diabetes
mellitus
0.000027 0.034 ABCC8. ABCG1. ABT1. ADRA1B. ADRA1D. AGT. APOA5. ATP10A. BCL2. BCL2L11. BTC. BTN2A1. BTN3A2. CBLB.
CCR5. CD200. CD38. CD40. CNTNAP2. CYBA. E2F3. ENAH. FOXP1. FTO. GABRD. HFE. HFE2. HIST1H3A
(includes others). HTR2C. ICOS. IGF2-AS1. INS. INSR. KCNJ11. KIRREL3. KLF10. mir-154. mir-448. MTTP. PBX3.
PDE8A. PGM1. PIEZO2. PPARA. PPP3CA. PRDM10. PRSS16. PRUNE2. PXDNL. RGS1. RGS5. SELL. SOD1. TH.
THRB. TSPO. VEGFA. ZMYM2
58
angiogenesis
of bone
0.000032 0.034 BMP2. NOG. TGFB2. VEGFA 4
quantity of
metal ion
0.000071 0.043 ABCC8. ADRA1B. AGT. ATP2B3. BCL2. BTK. CAMLG. CCR5. CD247. CD38. CHGA. CX3CR1. CXCL13. DARC.
DCN. DVL1. EGF (includes EG:13645). FCER1A. GNA14. GNB1. IGF2. INS. INSR. KCNJ11. NTS. NUCB2. POMC.
PRL. PRNP. PTGDR2. RGS1. RYR3. SELL. SOD1. TRPM8. TXNIP. VAV3. VEGFA
38
development
of head
0.000069 0.043 BCL2. BCL2L11. BID. BMP2. BMPR1B. CD247. CHD7. CRYBB2. CX3CR1. DLX1. DNMT3A. EBF3. EGF (includes
EG:13645). FJX1. FTO. GJA3. H19. HESX1. IFT88. IGF2. IRX3. ITGA6. LUM. MITF. MYO5A. NOG. OGN. PAX5.
PROM1. PRRX2. PYGO1. SEMA5A. SOD1. STAT1. TGFB2. TH. THBS2. THRB. TUB. USH2A. VEGFA. WT1
42
migration of
cells
0.000057 0.043 ADI1 (includes EG:104923). AGT. APLP2. APPL1. ARHGAP5. B3GAT1. BCL2. BGN. BID. BMP2. BTC. BTK. CBLB.
CCR5. CD200. CD247. CD36. CD38. CD40. CD99. CHGA. CMA1. CNTNAP2. CSF2RA. CTBP2. CTNNA2. CTSG.
CX3CR1. CXCL13. DARC. DCDC2. DCN. DISC1. DLX1. DYX1C1. E2F3. EBF3. EGF (includes EG:13645). ELMO2.
FCER1A. FH. FHL2. GFRA1. GNA12. GRIA2. GZMB. HTATIP2. ICOS. IGF2. INS. INSR. ITGA6. KIAA0319. LAMA2. LPP.
LSP1 (includes EG:16985). LTF. LUM. LY96 (includes EG:17087). MAPK1. MNX1. MTAP. MYO10. MYO1F. NAV1.
NOG. NPTX2. NTS. NUCB2. PAEP. PDPN (includes EG:10630). PEX11B. PEX13. POMC. POU3F2. PPARA. PPM1F.
PRKCQ. PRKCZ. PRL. PRNP. PROK2. PTGDR2. PTGES. PTK2 (includes EG:14083). PVR. RASSF5. RGS1. SATB2. SELL.
SEMA5A. SOD1. STAT1. TDP2. TGFB2. THBS2. TIAM1. TNFAIP8. TNFRSF18. TNFRSF4. TNFSF13B. TSPO. UNC5C.
VASH1. VAV3. VEGFA. VIM. WWOX
108
cell movement0.000073 0.043 ADCY10. ADI1 (includes EG:104923). AGT. APLP2. APPL1. ARHGAP5. B3GAT1. BCL2. BGN. BID. BMP2. BTC.
BTK. CATSPER3. CBLB. CCR5. CD200. CD247. CD36. CD38. CD40. CD99. CHGA. CMA1. CNTNAP2. CSF2RA.
CTBP2. CTNNA2. CTSG. CX3CR1. CXCL13. DARC. DCDC2. DCN. DISC1. DLX1. DYX1C1. E2F3. EBF3. EGF (includes
EG:13645). ELMO2. ENAH. FCER1A. FH. FHL2. GFRA1. GNA12. GNB1. GRIA2. GZMB. HTATIP2. ICOS. IFT88. IGF2.
INS. INSR. ITGA6. KIAA0319. LAMA2. LPP. LSP1 (includes EG:16985). LTF. LUM. LY96 (includes EG:17087). MAPK1.
MNX1. MTAP. MYO10. MYO1F. NAV1. NCK2. NOG. NPTX2. NTS. NUCB2. PAEP. PDPN (includes EG:10630). PEX11B.
PEX13. POMC. POU3F2. PPARA. PPM1F. PRKCQ. PRKCZ. PRL. PRNP. PROK2. PTGDR2. PTGES. PTK2 (includes
EG:14083). PVR. RASSF5. RGS1. RGS10. SATB2. SELL. SEMA5A. SOD1. SPAG16. STAT1. TAS1R3. TDP2. TGFB2. THBS2.
THRB. TIAM1. TNFAIP8. TNFRSF18. TNFRSF4. TNFSF13B. TSPO. UNC5C. VASH1. VAV3. VEGFA. VIM. WWOX
118
apoptosis 0.000069 0.043 ABCG1. ADCY10. ADI1 (includes EG:104923). ADRA1B. ADRA1D. AGPAT2. AGT. APPL1. ATXN1. BCL2. BCL2L11.
BCL2L13. BGN. BID. BIK. BMP2. BMPR1B. BTC. BTK. CACNA1A. CBLB. CCDC86. CCNI. CCNL2. CCR5. CD200.
CD247. CD36. CD38. CD40. CD5L. CD99. CDK11A/CDK11B. CSF2RA. CTBP2. CTSG. CX3CR1. CYBA. DACH1. DCN.
DLX1. DNMT3A. DUSP10. DVL1. E2F3. EGF (includes EG:13645). EPHA7. EPHX1. EPM2A. FABP1. FANCC. FBXL5.
FCER1A. FHL2. FOXP1. FSTL3. GFRA1. GNA12. GRIA2. GZMB. HFE. HSF2. HTATIP2. ICOS. IFNE. IGF2. IKBKE.
IL17RD. INS. INSR. IPPK. ITGA6. ITGB3BP. ITPK1. IVNS1ABP. KIFAP3. KLF10. LAMA2. LIG4. LSP1 (includes EG:16985).
LTF. LUM. MAGED1. MAGEH1. MAPK1. mir-154. mir-506. MITF. MLLT3. MNAT1. MTCH1. NELL1. NOG. NPTX2. NTS.
PAEP. PAWR. PAX5. PDCD6IP. PEX11B. PKN2. POLH. POMC. PPARA. PPM1F. PPP2R4. PPP3CA. PRAME. PRKCH.
PRKCQ. PRKCZ. PRL. PRNP. PRPF19. PRUNE2. PTGES. PTK2 (includes EG:14083). PUS10. RASSF5. RGS5. RNASEH1.
SELL. SGCG. SLC25A6. SMARCA2. SMOX. SOD1. SPAG16. ST14. STAT1. TFAP4. TGFB2. THBS2. TIAM1. TMEM109.
TMEM132A. TNFAIP8. TNFRSF18. TNFRSF4. TNFSF13B. TREX2. TRPS1. TSPO. TUB. TXNIP. UNC5C. VEGFA. VIM.
VPS13A. WT1. WWOX. XPO1. ZMYM2
153
quantity of
leukocytes
0.000076 0.043 AGT. BCL2. BCL2L11. BID. BIK. BST1 (includes EG:12182). BTK. CARD11. CBLB. CCR5. CD200. CD247. CD36.
CD38. CD40. CD5L. CRLF2. CX3CR1. CXCL13. DCN. DMD. DUSP10. FABP1. FANCC. FCER1A. FOXP1. GNA12.
HESX1. ICOS. IGF2. INS. ITGA6. KDM5A. KIFAP3. KLF10. LAMA2. LIG4. LSP1 (includes EG:16985). LUM. NOG.
PAWR. PAX5. PRKCQ. PRL. PRNP. PROK2. PTGDR2. PTGES. PTK2 (includes EG:14083). RASSF5. RGS1. RGS10.
SELL. SOD1. ST14. STAM. STAT1. TNFRSF4. TNFSF13B. TOX. TXNIP. VAV3. VEGFA. VPREB1. WWOX
65
A total of 823 genes surrounding the 603 top associated SNPs were put into the IPA software.
Surrounding genes were defined by either Grail (www.broadinstitute.org/mpg/grail/) or the Genome Browser (http://genome.ucsc.edu/). Gene families located in the
same region were manually curated so that only one gene in each family remained in each region, based on a similar official gene symbol.
*Hochberg Y, Benjamini Y. Statistics in medicine 1990; 9:811–8.
doi:10.1371/journal.pone.0070174.t005
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Table 8). Another gene present in these networks was the gene
encoding for the immune molecule CD40 (associated SNP
rs6065961, Table S1). CD40 has been shown to regulate immune
responses to another parasite, Leishmania Major, by shared
signaling through p38 MAPK and ERK1/2 [35]. CD40 also
regulates DUSP expression and activity, which in turn contribute
to anti-leishmanial functions [35]. It has been suggested that
Leishmania Major inhibits CD40-triggered p38 MAPK signaling
as part of an immune evasion strategy [36].
Another overrepresented category from GeneTrail was the
extracellular matrix (ECM) (Table 6). Also, in the two most
significant Ingenuity networks from the 603 marker analyses,
ECM molecules and matrix metalloproteinases (MMPs) were
included (Table 8). The ECM represents a major barrier to
parasites like amoebas and leishmania. Parasites produce a wide
variety of proteases to break down the ECM in order to access
essential nutrients and invade host tissue [37]. A different situation
when the ECM is degraded is during nutrient deprivation. In this
way the ECM can provide energy for starving host cells. Just like
gluten, the ECM has an unusually high proline content. MMPs
are enzymes, which break down ECM making proline readily
available as a nutritional source. Pandhare and co-workers have
shown that energy or nutrient stress activates MMPs as well as the
degradation of proline and furthermore demonstrated that, as the
levels of glucose decreased to 1 mM and lower in the medium,
intracellular proline increased almost 2-fold [38]. If gluten
lingering in the intestine conveys a signal of ECM degradation
(due to increased proline levels), several other mechanisms will
most likely signal that there is food available at the same time
(salivary secretion as one example is shown in Table 6). In this
case, the immune system will rule out starvation as a possibility
and the only other sensible option would be to search for an
invasive intruder breaking down the ECM. The autoantigen in
CD, TGM2, counteracts proteolysis and degradation of ECM by
crosslinking ECM proteins [39]. If DUSP10 and PRRL5 up-
regulate TNF-a and subsequently TGM2 [17,18,25], in CD, the
purpose may very well be for TGM2 to help prevent an apparent
or illusory pathogenic invasion. It has also been shown that down-
regulation of SVIL protects against ECM invasion by pathogens
[40]. In our gene expression analysis SVIL was nominally
significantly down-regulated in cases (Table 9).
When the body ‘‘senses’’ a pathogen disturbing energy balance
or breaking down ECM, but there are no pathogenic antigens
present, maybe there could be a risk that ‘‘self’’ antigens become
our immune systems futile attempt to rid the perceived pathogen.
In HLA-DQA1*02/05 and HLA-DQB1*02 carriers, peptides
derived from TGM2 could constitute such ‘‘self’’ antigens. It is
possible that individuals carrying other HLA molecules still
respond to this ‘‘phantom pathogen’’ and that under these
circumstances, various other antigens present in the intestine at
the time could become triggers of other autoimmune diseases. If
the expression or presence of an autoantigen, like TGM2, was
stimulated by the disturbed proline/glutamine homeostasis, it can
explain why symptoms in CD also disappear by withdrawal of
gluten.
Conclusion
At least four major functional components together with gluten,
all seem to play a role in forming an individual’s risk for CD:
1) polarity and epithelial cell functionality, e.g. nutrient/vesicle
transport, proliferation and apoptosis, important for cell
migration from the crypt to the shedding (apoptosis) at the
apical villi.
2) intestinal smooth muscle, which is important for the
movement of the bowel as well as the villi.
3) growth and energy homeostasis, which includes proline and
glutamine metabolism, and finally
4) the innate and adaptive immune system.
Table 7. Biological functions of genes surrounding SNPs from the two-locus interaction. Results from GeneTrail.
Category rank Subcategory expected observed
p-value
(raw) enrichment Genes
KEGG 1 Amoebiasis 1.01 4 0.0178 up ACTN1 CTSG GNA14 TGFB2
KEGG 2 T cell receptor signalling 1.04 4 0.0196 up CBLB CD247 ICOS VAV3
KEGG 3 PPAR signaling pathway 0.66 3 0.0282 up APOA5 CD36 FABP1
KEGG 5 Ubiquitin mediated proteolysis 1.34 4 0.0438 up CBLB KLHL9 TCEB1 UBR5
KEGG 6 Primary immunodefciency 0.34 2 0.0441 up BTK ICOS
KEGG 7 Basal transcription factors 0.35 2 0.0465 up GTF2B TAF7L
NIA human
disease
gene sets
1 Hyperlipoproteinemias 0.07 2 0.0017 up APOA5 FABP1
NIA human
disease
gene sets
2 Diabetes Mellitus Type 2 2.80 6 0.0493 up APOA5 CCR5 CD36 CMA1 FABP1 TH
A total of 187 genes from the interaction analysis were put into the GeneTrail software.
Surrounding genes were defined by either Grail (www.broadinstitute.org/mpg/grail/) or the Genome Browser (http://genome.ucsc.edu/). Gene families located in the
same region were manually curated so that only one gene in each family remained in each region, based on a similar official gene symbol.
Size of test set: 186 (173 known). Number of known ref. IDs: 44829.
KEGG: number of annotated genes in test set: 52. Genes in reference set: 5405.
NIA human disease gene sets: number of annotated genes in test set: 20. Genes in reference set: 1487.
doi:10.1371/journal.pone.0070174.t007
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Table 8. The top four networks generated by the Ingenuity IPA software (allowing only direct connections between proteins/
genes).
1: Cell Morphology,
Cellular Assembly and
Organization, Hair and
Skin Development and
Function. Ingenuity Score:
155, 109 focus molecules.
ABT1,ACAP3,Ant,APLP2,APOA5,ARID1B,ASB6,
ASPN,ATXN1,BASP1,BGN,BICD2,BIK,C1q,Cbp/p300,CCDC50,CCNL2,C
D200,CD5L,CDK11A/CDK11B,CEP55,CHGA,COL22A1, collagen, Collagen type I,Collagen type,IV,Creb,
CSF2RA,CXCL13,CYBA,CyclinA,CyclinE,DACH1,DCAF6,DCN,DDB1,DPP6,DUSP10,
E2F3,E2f,EAPP,EFCAB7,ELOVL6, EPB41L2, FABP1,FCER1A,Fibrinogen,FOXD3,GGA1 (includes
EG:106039),GLS,GLTPD1,GRIA2,GSPT2,GSTT2/GSTT2B,GTF2B,HESX1,
HIST1H3A (includes others),Histone h3,Histone h4,HMG20B,Holo
RNApolymeraseII,HTATIP2,IGF2,Immunoglobulin,INS,Insulin,ITGA6,ITG
A10,ITGB3BP,IVNS1ABP,KDM5A,KLF12,LAMA2,Lamin b, Laminin1,Laminin,LBR (includes EG:368360),
LIG4,LSAMP,LUM,MMP17,Mmp,MMP23B,MNAT1,MTTP,MVD,N-
cor,NAP1L3,NBPF11, (includes others),
NCOA5,NFkB(complex),NFRKB,NTS,PAX5,PBX3,PCBD2, PKIB,POU2F1, POU3F2,
PPARA,PPM1F,PRL,PRMT3,PRMT8,PRNP,PTGES,PVR,pyruvate kinase, Rb,RBM8A,RGS1,RNA polymerase
II,RNF126,SLC25A6,SMC2,SRSF7,SYT8,TAF7L,TCEB1,TEAD4, Tgf beta,TGFB2,TGFBRAP1,THBS2,thymidine,
kinase,thyroid hormonereceptor,TNFRSF4,TRHDE,TSPO,TXNIP,Ubiquitin,UBR5,Vegf,VEGFA,
VIM,VPREB1,VPS37C,WT1,ZRANB1
2: Cell Signaling,
Molecular Transport, Vitamin
and Mineral Metabolism.
Ingenuity score: 97,
86 focus molecules.
14-3-3,Actin,ADRA1B,ADRA1D,ADRBK2,AGT,AKAP13,Akt,alcohol group acceptor phosphotransferase,
ACTN1, Alpha tubulin,Angiotensin II
receptor type 1,Ap1, ARHGAP5, ARHGEF18,BCL2,BCL2L11,BTK,Calmodulin,CaMKII,CARD11,caspase,C
BLB,CCR5,CD3,CD6,CD36,CD38,CD40,CD247,chemokine,CTSG,CX3CR1,DARC,
DISC1,DMD,DVL1,Dynamin, Dynein,dystroglycan,EGF (includes
EG:13645),EPB41L3,EPHA7,ERK,ERK1/2,estrogen receptor,F Actin,FCRL4,FHL2,Focal adhesion kinase,G
protein,Gap,GLRX3,GNA12,GNB1,Gpcr, GPR20,GPR27,GPR33,GPR45,GPR111,GPR115,GPR149,GPR161,growth
factor receptor,GZMB,Hsp70,Hsp90,HTR2C, ICOS,Iga,INADL,INSR,JAK,Jnk,KLF10,LIN7A,LPHN2,LTF,MAPK1,
Mapk,MHC Class I (complex),MHC Class II (complex),MITF,Mlc,MRC1 (includes EG:100286774),
MYT1L,NADK,NCK2,Nfat(family),NMDA
Receptor,O3FAR1,OR51E2, P38 MAPK, p85 (pik3r), Pak,PAWR,PDCD6IP,PDK1,PDPN (includes EG:10630),PI3K
(complex),PI3K p85,Pkc(s),PKN2,PLC gamma,POMC,PP2A,PPP3CA,PRKCH,PRKCQ,PRKCZ,PTGDR2,PTK2
(includes EG:14083),Rac,Ras,RASSF5,Rxr,SGCG, SMARCA2,SOD1,Spectrin,
STAM,STAT1,STAT,STAT5a/b,TAB1,TAS1R3,TCR,TH,THRB,TIAM1,TIMM8A,TNNT3,Troponin t, TUB,Tubulin,
UTRN,VAV3,VAV,VN1R5
3: Cellular Assembly
and Organization, Cellular
Function and Maintenance,
Developmental Disorder.
Ingenuity score:
77, 69 focus molecules.
ABCG1,ABTB2,ACAD9,ACAD10,ACADSB,ADI1 (includesEG:104923),AGPAT2,AGPAT3,AGPAT4,
AGPAT5,AGPAT6,ALDH18A1,ARL6,ATL2,B9D1,BAIAP2L1,BCL2L13, BRP44,C10orf35,C10orf88,
CAMLG,CC2D2A,CCBL2,CCNI,CDH18,CDK5RAP2,CHIC2,CNTNAP2,CPSF3L,CRYL1,
CTNNA2,DDX46,DMXL1,DOCK4,DSE,EBNA1BP2,ELMO2,ELMO3,ERGIC1,
ERGIC2,ERGIC3,FAM125A,FAM125B,FAM175B,FBXO8,GEMIN6,GEMIN8,GLA,GNL1,HAUS2,H
AUS3,HAUS5,HAUS7,HAUS8,HCN1,HCN2,HERC3,HERC4,HERC6,HFE,HNRNPH2,HNRPLL,
IFT20,IFT52,IFT57,IFT88,IL13RA1,IL13RA2,INTS2,INTS9,LPP,LSG1,MAD2L1BP,MAGEH1,MAOA,MCAT,MICAL3,MKS1
(includes EG:287612),MOAP1,MRPL23,MRPL20 (includes EG:39477),MRPL3 (includes EG:11222),MRPL40
(includesEG:18100),MRPS21,MTAP,MYLIP,MYO1F,NDUFAB1, OSTF1,OXA1L, PALM,PCMTD1,PHKA1,PHRF1, PIGQ,PIGY,PPAP2B,
PRAME,PTPN14,PYGB,REEP5,RIC3,RNF122,RNF166,RTN3,SARS2,SCYL3,SEC24A,SEC24B, SEMA5A, SERINC1, SGSH,SHPRH,SIL1
(includesEG:100334837),SIPA1L2,SIPA1L3,SLC17A2, SLC23A2,SMEK2,SMOX,SSU72,STK19,TBC1D15,TCTN2,TFAP4,
TFR2,TGM3,THAP5, TIPRL, TOP3B,TRIM17,TRIM44,TUBG2,UBC,USP44,VEZT,VPS37A,ZDHHC8,Z
MIZ1,ZNF259
4: Post-Translational
Modification, Carbohydrate
Metabolism, Lipid
Metabolism. Ingenuity
score: 74, 67 focus molecules.
AGXT2L1,AHCYL2,ANGEL1,ANKRD17,ANKRD34A,ARMC9,ASXL1,ASXL2,AURKAIP1,B3GALT6,
BAP1,BTN3A2,C15orf41,C1orf112,C1orf198,C2CD2,C9orf106,CCDC86,CCNDBP1,CCPG1,CENPP,COX20 (includes
EG:116228),CTU2,CXXC4,DAK,DENND3,DHRS3,DLST,EFR3B,ELF2,ENDOV,FBXL4,FIS1 (includes EG:288584), FTO,GDAP1,
HAT1,HSPA2,IER3IP1,IFIH1,IMP3,INPP5A,INPP5B,INPP5E,INPP5K,IPO4,IPPK,KANK4,KCNK10,KDM1B,KHNYN,LMBR1,MB21D2,
MCF2L,ME
D20,METTL10,MRPL15 (includes EG:27395),MRPS18A,MRPS9
(includesEG:301371),MTCH1,MTMR8,MTMR9,PABPC5,PAN2,PITRM1,
PMPCA,POLR3GL,PPM1G,PRDM10,PRPSAP2,PRUNE2, PSMB10,
PSTK,PUSL1,PXDNL,RCN3,RPL28,SAR1B,SCAF4,SCNN1D,SDR39U1,
SEC13,SEC16A,SEC16B,SEC23A,SIRT6,SLC35C2,SLC39A10,SLC45A4,SLC6A3,SYF2 (includes
EG:170933),SYNGR1,SYNJ2,TAPT1,TMEM70, TMEM132A,TPTE/
TPTE2,TRMT5,TSPAN9,TTYH2,TTYH3,TXNDC15,UBC,UBE2O,UCHL1,UCHL3,USP2,USP3,USP5,USP6,
USP10,USP13,USP16,USP18,USP21,USP24,USP25,USP28,USP30,USP32,USP33,USP34,USP35,USP36,USP37,USP38,
USP40,USP42,USP44,USP45,USP47,USP48,USP53,USP54,USP27X,USP9Y,XXYLT1,ZC3H13,ZNF131,
ZNF334,ZNF608
The results of the network analysis included our genome-wide significant finding (DUSP10) within the top scoring network. P38 MAPK which interacts with DUSP10 is
included in the second top network. Also the MHC class II complex is part of the second network. Genes within ours (P38 MAPK and DUSP10) and previously identified
genome-wide significant regions are marked in italic, bold text. Only bold text show genes involved in amoebiasis. Underlined genes showed differences in our gene
expression analysis (Table 9).
Rank; Top functions; Ingenuity score; Number of focus molecules; Molecules in Network.
doi:10.1371/journal.pone.0070174.t008
Celiac Disease Genome-Wide Linkage and Association
PLOS ONE | www.plosone.org 15 August 2013 | Volume 8 | Issue 8 | e70174
A slight dysfunction combining these categories together with
gluten consumption would result in a metabolic imbalance which
in turn could convey enough stress or ‘‘danger signal’’, to trigger
the immunological process and tissue destruction. A schematic
illustration showing a rough outline of a possible disease model is
presented in Figure 6.
In this study, we identified DUSP10 to be significantly associated
with celiac disease. We also identified mechanisms, which we
believe influence the risk of developing disease. Our data points
towards genes that are involved in cancer as well as metabolic and
cardiovascular diseases. Besides understanding how they work in
celiac disease, our findings could also have consequences for these
other common diseases.
Whole genome analysis allows for discovering completely
unknown mechanisms behind disease. Even if the discovered
genes and gene variants won’t be able to predict who will develop
disease in the future, they can be used to identify the underlying
molecular pathways that influence disease. These molecular
pathways would then be valuable targets for drug intervention.
Our data provides new insights and hypotheses to the research
field of CD and autoimmunity. However, the functional variants
behind associations as well as mechanisms causing differences in
gene expression and if and how these are relevant for disease,
remains to be identified.
Materials and Methods
Ethics Statement
The regional ethics board in Gothenburg approved this study
and participants in the study gave written informed consent after
being fully informed about the aim of the study. For all children in
the study, parental written consent was obtained.
Study Population
A total of 106 families with multiple affected individuals, mostly
nuclear families with an affected sib pair (ASP) were collected from
Sweden and Norway. There were 403 subjects and 97 families
with DNA to complete the analysis. A total of 226 of the family
members had CD, including 20 parents. The makeup and
selection process regarding the families has been described
previously in detail [41].
Small-intestinal biopsies, for the gene expression analysis, were
collected at four pediatric clinics in Sweden: Ska˚ne University
Hospital in Malmo¨, Sach’s Childrens’ Hospital and Karolinska
Figure 4. Gene expression results. Fold change on the y-axis is plotted for each individual in the two groups, 46 CD cases and 52 control
patients. Each circle in the graph represents an individual. The mean expression value of the control group is set to 1.
doi:10.1371/journal.pone.0070174.g004
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University Hospital in Stockholm and Sahlgrenska University
Hospital in Gothenburg. For gene expression calculations, we
decided to use case-control status based on anti-tTG IgA and IgG
antibody levels in plasma using the Radio-Binding Assay (RBA)
[42,43]. Patients being both tTG IgA and IgG positive (.4 U/ml)
were included as cases (we use the term ‘‘CD autoimmunity’’ for
these cases [44]) and all other individuals were included as disease
controls. The LPP gene was run in a first set of 42 cases (30
females, 12 males) and 38 control patients (21 females, 17 males).
Cases and controls had a mean age of 7.3 and 11.1 years
respectively. The remaining genes were run in a second set of 46
cases (25 females, 21 males) and 52 control patients (27 females, 25
males) with a mean age of 7.4 years for cases and 11.8 years for
control patients at the time the biopsy was taken.
Gene Expression Analysis
We performed quantitative gene expression analysis using
duodenal biopsies from CD autoimmunity patients and control
patients. Biopsies were immediately put in RNAlater solution (Life
Technologies, CA, USA). Total RNA was extracted using the
miRNeasy Mini Kit (QIAGEN, Germany). RNA was converted to
cDNA and quantitative PCR was run using TaqMan chemistry
and the ABI7900 SDS instrument (Life Technologies, CA, USA).
Seven control genes were evaluated using GeNorm [45] (ACTB
(Hs00357333_g1), B2M (Hs99999907_m1), EPCAM
(Hs00158980_m1), GUSB (Hs99999908_m1), HPRT1
(Hs99999909_m1), MUC1 (Hs00159357_m1), PGK1
(Hs99999906_m1)) and the geometrical mean of ACTB, EPCAM,
and PGK1 were selected as reference for the relative quantification
analysis (Delta-Delta Ct method). A total of 34 expressed genes
located close to some of the most significantly associated SNPs
were evaluated (Table 9). The top associated genes from our
Linkage GWAS (DUSP10, SVIL, PPP1R12B) were selected as well
as several genes from the two-locus interaction analysis and
pathway analyses including LPP which is the top associated from
the GWAS by Dubois et al. Also the RGS genes (RGS1, 2 and 5)
and GLS show genome-wide association in the study by Dubois
et al and are also present in our two-locus and pathway analyses.
Genotyping and Imputation
Samples were genotyped using two different SNP arrays, 211
samples with Human Omni Express and 192 samples with Human
660W-Quad (Illumina Inc, CA, USA). A total of 308,246 markers
were available on both arrays and were therefore genotyped in the
entire material. For the remaining 682,470 and for sporadic
missing values we performed genotype imputation using the
Impute 2 software [46], with the Hapmap 2 (rel. 24 Build 36) as a
reference.
All individuals in the same family were located on the same
plate. Quality control was first performed separately for the two
arrays. SNP markers with less than 97% call rate in either of the
two arrays were excluded.
Mendelian errors were detected by PLINK [47], 125,874
family-wise mendelian inconsistencies were set to missing (in each
family the genotypes were set to missing for all subjects if there
were any mendelian inconsistencies for a specific SNP).
Statistical Analysis
Linkage. For the linkage analysis only markers from both
platforms were considered. From this set of 271,078 common SNP
markers a LD pruned set of 105 539 SNPs were selected using
PLINK. Parameters were a window size of 50 and R2,0.5. The
Decode genetic map as supplied by Illumina was used to run non-
parametric linkage using Merlin version 1.1.2 [48] with the NPL
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all method [49]. Marker allele frequencies were estimated from the
founders.
Transmission Disequlibrium Test (TDT). Spielman et al
introduced the Transmission Disequilibrium Test (TDT) in 1993
[50].
The imputation analysis provides us with (posterior) probabil-
ities for each of the possible genotypes at each locus and to utilize
all posterior probabilities, we performed an analysis where we use
the expected values of the transmission counts. The test statistic
will then have the following form,
Timp~
E b½ {E c½ ð Þ2
E b½ zE c½  , ð1Þ
Timp has approximately the same distribution as the test statistic
T in [50].
Stratified TDT. We implement a stratified TDT analysis
where trios are split into a low-risk and a high-risk group based on
the HLA genotype of the affected offspring. Children carrying the
HLA-DQA1*02/05 risk allele and homozygous for the HLA-
DQB1*02 risk allele (i.e. individuals carrying the DR3/DR3 or
the DR3/DR7 haplotypes) were put in the ‘‘high-risk’’ group and
the remaining children were put in the ‘‘low-risk’’ group. The
rationale behind this is explained in the introduction and further
information about this stratification can be found in our previous
Linkage study [14]. A standard TDT analysis, with the 0.95 cut-off
for imputation probabilities, was applied to each of these groups
using PLINK [47].
Test for two-locus interaction. To examine possible
interactions between marker variants, we used a pairwise test
based on the one introduced by Kotti [51]. Consider two biallelic
markers without linkage disequilibrium between their alleles. In
the general model MG the penetrance matrix has 9 parameters,
f G~
f00 f01 f02
f10 f11 f12
f20 f21 f22
2
64
3
75,
Let n be the 363 matrix of genotype counts among the cases for
the two markers, and let m be the corresponding matrix for the
non-transmitted allele combinations. The likelihood for the models
is
Figure 5. NPL results. Non-Parametric Linkage score displayed as –log10(p-value) on the y-axis and chromosome 1–22 and X on the x-axis.
doi:10.1371/journal.pone.0070174.g005
Table 10. Non Parametric Linkage (NPL) results.
chr from(Mb) to(Mb) max NPL p-value
6a 12,5 52,6 5,42 3,03E-08
5 124,5 149,3 3,33 4,36E-04
1 200,2 231,8 3,12 9,20E-04
11 122,2 130,2 2,95 1,59E-03
9 30,3 34,7 2,82 2,40E-03
4 96,5 111,3 2,81 2,46E-03
3 104,7 108,6 2,70 3,49E-03
14 85,7 86,4 2,57 5,16E-03
6 160,4 161,0 2,54 5,50E-03
11 77,6 78,4 2,48 6,64E-03
18 55,0 55,1 2,45 7,20E-03
1 29,7 29,9 2,42 7,87E-03
2 127,0 127,1 2,41 8,00E-03
2 106,3 106,4 2,37 8,89E-03
Regions showing significant linkage (the HLA region only) and putative linkage
(nominal p,0.01. Regions in the table are defined as the Megabase (Mb)
interval showing a nominal p,0.01. Neighbouring regions were merged if
,15 Mb pairwise distance.
Max NPL – the maximum Z score across the region between the positions ‘from’
and ‘to’.
p-value – the p-value for the max NPL score.
a = The HLA region.
doi:10.1371/journal.pone.0070174.t010
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L(f )~P
i,j
fijP(AiBj)P
k,l fklP(AkBl)
 !nij
P(AiBj)
mij : ð2Þ
For this analysis we use one affected subject from each family
and markers were chosen based on the expected counts TDT
(equation 1) and three different inclusion criteria:
1. P-value less than 3.061024.
2. P-value less than 0.01 in our analysis and with a p-value less
than 0.05 in the GWAS by Dubois et al. [3] and if the product
of these p-values were less than 5.061025 and the association
were in the same allelic direction.
3. An allele transmission ratio of ,0.2 or .5 combined with a p-
value less than 261023.
We defined 383 regions using the inclusion criteria above (Fig. 2
and Table S1) a region consisted of a set of markers where the
distance between adjacent markers was less than 100 kb. With
these regions defined we analyzed all pairwise interactions using a
Likelihood Ratio (LR) tests comparing the following four models:
N M0: None of the two loci is associated with CD,
N MR: Heterogeneity model [52], with penetrance
fij~aizbj{aibj ,
where ai and bj are the penetrance factors for the genotypes Ai and
Bj [53] respectively.
N MM: Multiplicative model,
N MG: the general model.
The restricted model used in [51] is the multiplicative model.
We use the MG-versus-MM test to filter out false positives, based
on that if one or both of the SNPs were marginally significant by
chance, then the joint distribution (penetrance) of these markers
should follow a multiplicative model.
We have the likelihood ratio statistic
Tjk~{2 log
maxLj
maxLj
Tjk will follow a x
2 distribution under the restricted model if Mj is
nested in Mk. The maximum likelihood estimates of the
penetrance parameters and allele frequencies do not have a
simple explicit expression, so to maximize the likelihoods we use
the function optim in the statistical software R.
Gene Selection
Out of the 603 SNPs selected from the three inclusion criteria
(Fig. 2 and Table S1), we were able to identify genes surrounding
Figure 6. Proposed disease model. Illustrating a possible scenario for disease development. Genetic variation contributing susceptibility to
disease can be found in at least four, somewhat overlapping, biological functions. The result is an ‘‘overload’’ or imbalance of proline vs glutamine.
Due to the abundance of proline within the extracellular matrix (ECM) as well as in gluten, the proline from gluten is interpreted as degradation of
ECM. When the body is not starving, the ECM is normally not degraded, unless there is a pathogen attempting to break through this barrier. The
immune system mounts an attack against an invasive ‘‘phantom pathogen’’ which is believed to degrade the ECM. When proline is catabolized,
reactive oxygen species (ROS) are released. In order to start re-building and crosslinking ECM molecules, Tissue transglutaminase (TGM2) expression is
up-regulated by TNFa which in turn is stimulated by DUSP10 and Protor-2 (PRR5L). This rebuilding of the ECM counteracts the degradation by the
imagined pathogen. However, the phantom pathogen remains and the adaptive immunity is brought in. Searching for antigens, it finds an
abundance of TGM2 beside the ECM and forms antibodies against its own soldier. Some susceptibility genes can be found in the center of this model
and some can be found within the spiral. Genes like HLADQ and other genes from the adaptive immunity are likely to be found in the spiral.
doi:10.1371/journal.pone.0070174.g006
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444 SNPs using GRAIL [54]. Grail uses known recombination
hotspots in order to limit the region of interest surrounding each
SNP marker. Genes around the remaining SNPs were identified
with the Genome Browser (http://genome.ucsc.edu) and the 5
closest genes within 250 kb from the associated SNPs were
included. In cases where there were no genes within this distance
we included the closest gene.
Pathway Analysis
We analyzed connections between genes in different regions,
using GeneTrail [13] and the Ingenuity Pathway Analysis (IPA)
software (Ingenuity Inc. CA, USA). Within each associated region,
all but one gene from the same gene family were removed. This
was done in order not to amplify the significance of homologous
gene clusters, (i.e. chemokine receptor-, interferon- and histone-
gene clusters).
URLs
PLINK (http://pngu.mgh.harvard.edu/purcell/plink/)
KEGG (www.genome.jp/kegg/)
Gene Ontology (www.geneontology.org/).
GWAS catalog, http://www.genome.gov/gwastudies/
GRAIL (http://www.broadinstitute.org/mpg/grail/)
SNAP (http://www.broadinstitute.org/mpg/snap/ldplot.php/)
GeneTrail (http://genetrail.bioinf.uni-sb.de/)
Supporting Information
Table S1 A selection of 603 top associated SNPs and the
two top HLA SNPs. Based on three inclusion criteria, 603 SNP
markers and 383 regions were identified. Our TDT results, where
T and U are the expected transmission counts (based on all the
posterior imputation probabilities) and corresponding results from
Dubois et al. [3].
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